Health
GSK Prevails in Second Zantac Cancer Case to Go to Trial
- A jury found GSK not liable for a woman’s colorectal cancer
- Zantac cases have unnerved investors, weighed on GSK’s stock
Zantac tablets.
Photographer: Gabby Jones/BloombergThis article is for subscribers only.
GSK Plc convinced an Illinois jury that the former heartburn drug Zantac was not liable for a woman’s colorectal cancer in a second trial win for the British drugmaker.
It comes just over two months after jurors in Chicago also found that GSK and Boehringer Ingelheim GmbH weren’t liable for another woman’s illness.